

Indian Immunologicals invests Rs 700 Cr in new animal vaccine facility in Hyderabad

10 October 2022 | News

Doubling capacity of Foot and Mouth Disease vaccine for cattle to meet vaccine security of the nation

Indian Immunologicals Limited (IIL) has announced that the company will invest about Rs 700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad - the "Vaccine Hub of the World", to meet the vaccine security of the nation against economically important diseases such as Foot and Mouth disease (FMD) and other emerging diseases. The facility will create total employment for around 750 people.

The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for Drug substance (DS) production and respective fill-finish.

IIL's intended new facility, in Genome Valley Phase 3, will add another 300 million doses/annum of FMD vaccine to its capacity. The existing facility in Gachibowli already has a capacity of 300 million doses. Production is scheduled to commence in the 3rd year.

Dr K. Anand Kumar, Managing Director, IIL mentioned, "IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers

several thousands of crores".

-